Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Q & A Session for Hematologic Malignancies

December 6th 2017

MRD Testing in Hematologic Malignancies

December 6th 2017

Phase III Data for Relapsed/Refractory Myeloma

December 6th 2017

Key Studies in Newly-Diagnosed Multiple Myeloma

December 6th 2017

Daratumumab for Smoldering Myeloma

December 6th 2017

KRd for High-Risk Smoldering Myeloma

December 6th 2017

AML Studies: BiTE Antibodies and Age for Transplant

December 6th 2017

AML Studies: FLT3 Inhibitors

December 6th 2017

Acute Myeloid Leukemia: Novel Targeted Therapies

December 6th 2017

NHL Studies: CAR T Therapy, Rituximab Maintenance, & PD-L1

December 6th 2017

New Data for Mantle Cell Lymphoma

December 6th 2017

Hodgkin Lymphoma: Upfront Brentuximab Vedotin + AVD

December 6th 2017

Pre-Conference Perspectives on Hematologic Malignancies

December 6th 2017

Dr. O'Connor Discusses Acalabrutinib in MCL

December 6th 2017

Owen O'Connor, MD, PhD, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).

Dr. Shah Discusses Sequencing for MCL

November 18th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the sequencing of agents for patients with mantle cell lymphoma (MCL).

Dr. O'Connor on Recent FDA Approvals in MCL

November 15th 2017

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the recent FDA approval of acalabrutinib (Calquence) for patients with mantle cell lymphoma (MCL).

Dr. Epperla on Treatment Following Ibrutinib in MCL

November 1st 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the next steps for patients with mantle cell lymphoma (MCL) who fail ibrutinib (Imbruvica).

FDA Approves Acalabrutinib for Mantle Cell Lymphoma

October 31st 2017

The FDA has granted an accelerated approval to acalabrutinib as a treatment for adult patients with mantle cell lymphoma following at least 1 prior therapy.

Dr. Tam on the Toxicity of Ibrutinib Plus Venetoclax in MCL

October 25th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities associated with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Goy Shares Insight on Novel Therapies in MCL

October 25th 2017

Andre Goy, MD, discusses the excitement surrounding novel therapies on the horizon in MCL.